Work

1134P Safety and efficacy of low dose (LD) ipilimumab (Ipi) + pembrolizumab (pem) in checkpoint inhibitor (CPI) naïve patients (pts) with melanoma brain metastases (MBM)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.2268

Authors: I.C. Glitza, D. Milton, V. Honaker, S. Turner, T. Hennegan, T. Beckham, R. Amaria, S. Patel, A. Diab, M. Wong, J. Mcquade, C. Yee, M. Davies, E. Burton, H.A. Tawbi

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4387810956

FWCI: 0.352

Cites:

Cited by: 3

Related to: 10